NCT03840837View on ClinicalTrials.gov

Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease

PHASE4CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

May 2, 2019

Primary Completion Date

April 1, 2020

Study Completion Date

April 1, 2020

Conditions
Parkinson DiseaseParkinson Disease Dementia
Interventions
DRUG

Rivastigmine transdermal patch

Titration of transdermal rivastigmine, as per arm description.

Trial Locations (1)

21201

University of Maryland School of Medicine, Dept. of Neurology, Baltimore

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Maryland, Baltimore

OTHER

NCT03840837 - Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease | Biotech Hunter | Biotech Hunter